汉森制药：在产品研发方面，公司中药新药苁蓉颗粒正处于工艺中试放大研究阶段

Group 1 - The company has been asked about the proportion of innovative drugs in its R&D plans for the year [2] - The company stated that its traditional Chinese medicine new drug, Cangrong Granules, is currently in the process of pilot-scale research [2] - Further details regarding the company's R&D plans will be available in the 2024 annual report [2]